Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and AstraZeneca's ENHERTU has shown significant progression-free survival benefits in HR positive, HER2 low metastatic breast cancer, according to the DESTINY-Breast06 trial. Additional data from DESTINY-Breast03 and DESTINY-Breast07 trials reinforce ENHERTU as a standard of care in the second-line setting and highlight its potential in the first-line setting.
June 03, 2024 | 6:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's ENHERTU has demonstrated significant clinical benefits in HR positive, HER2 low metastatic breast cancer, reinforcing its position as a standard of care in the second-line setting and highlighting its potential in the first-line setting.
The positive clinical trial results for ENHERTU are likely to boost investor confidence in AstraZeneca, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100